Maravai LifeSciences (NASDAQ:MRVI) Coverage Initiated by Analysts at Wolfe Research

Analysts at Wolfe Research initiated coverage on shares of Maravai LifeSciences (NASDAQ:MRVI) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a “peer perform” rating on the stock.

A number of other analysts have also recently issued reports on the stock. Robert W. Baird reduced their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Royal Bank of Canada reduced their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. The Goldman Sachs Group reduced their price objective on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, October 8th. Finally, Morgan Stanley cut shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $11.00 to $10.00 in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.33.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $5.63 on Thursday. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.42 billion, a PE ratio of -3.43 and a beta of 0.02. The company has a 50 day moving average price of $7.92 and a two-hundred day moving average price of $8.46. Maravai LifeSciences has a 12-month low of $4.68 and a 12-month high of $11.56.

Insider Buying and Selling

In related news, insider Carl Hull bought 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the transaction, the insider now owns 175,000 shares of the company’s stock, valued at $987,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.63% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. QRG Capital Management Inc. increased its holdings in Maravai LifeSciences by 11.7% in the 1st quarter. QRG Capital Management Inc. now owns 17,143 shares of the company’s stock valued at $149,000 after buying an additional 1,796 shares during the period. Creative Planning boosted its stake in shares of Maravai LifeSciences by 4.4% in the 3rd quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after purchasing an additional 1,881 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Maravai LifeSciences by 310.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock valued at $26,000 after purchasing an additional 2,711 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Maravai LifeSciences by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,595 shares of the company’s stock valued at $639,000 after purchasing an additional 3,575 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its stake in shares of Maravai LifeSciences by 0.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock valued at $4,320,000 after purchasing an additional 3,725 shares in the last quarter. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.